-
Signature
-
/s/ Christiana Stevenson, Attorney-in-Fact
-
Issuer symbol
-
VRTX
-
Transactions as of
-
13 Nov 2025
-
Net transactions value
-
-$25,799,237
-
Form type
-
4
-
Filing time
-
17 Nov 2025, 16:12:06 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| LEIDEN JEFFREY M |
Executive Chairman, Director |
C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON |
/s/ Christiana Stevenson, Attorney-in-Fact |
17 Nov 2025 |
0001242825 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
VRTX |
Common Stock |
Options Exercise |
$1,792,592 |
+19,688 |
+82% |
$91.05 |
43,714 |
13 Nov 2025 |
Direct |
|
| transaction |
VRTX |
Common Stock |
Sale |
$8,156,396 |
-18,528 |
-42% |
$440.22 |
25,186 |
13 Nov 2025 |
Direct |
F1, F2, F3 |
| transaction |
VRTX |
Common Stock |
Sale |
$511,618 |
-1,160 |
-4.6% |
$441.05 |
24,026 |
13 Nov 2025 |
Direct |
F1, F2, F4 |
| transaction |
VRTX |
Common Stock |
Options Exercise |
$1,259,677 |
+13,835 |
+58% |
$91.05 |
37,861 |
14 Nov 2025 |
Direct |
|
| transaction |
VRTX |
Common Stock |
Options Exercise |
$3,440,814 |
+39,769 |
+105% |
$86.52 |
77,630 |
14 Nov 2025 |
Direct |
|
| transaction |
VRTX |
Common Stock |
Sale |
$14,192,630 |
-32,234 |
-42% |
$440.30 |
45,396 |
14 Nov 2025 |
Direct |
F1, F2, F5 |
| transaction |
VRTX |
Common Stock |
Sale |
$9,413,996 |
-21,330 |
-47% |
$441.35 |
24,066 |
14 Nov 2025 |
Direct |
F1, F2, F6 |
| transaction |
VRTX |
Common Stock |
Sale |
$17,680 |
-40 |
-0.17% |
$442.00 |
24,026 |
14 Nov 2025 |
Direct |
F1 |
| holding |
VRTX |
Common Stock |
|
|
|
|
|
440 |
13 Nov 2025 |
401(k) |
|
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
VRTX |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-19,688 |
-59% |
$0.000000 |
13,836 |
13 Nov 2025 |
Common Stock |
19,688 |
$91.05 |
Direct |
F7 |
| transaction |
VRTX |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-13,835 |
-100% |
$0.000000 |
1 |
14 Nov 2025 |
Common Stock |
13,835 |
$91.05 |
Direct |
F7 |
| transaction |
VRTX |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-39,769 |
-38% |
$0.000000 |
63,781 |
14 Nov 2025 |
Common Stock |
39,769 |
$86.52 |
Direct |
F7 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: